Get the Stockscreener App
2.86
7.44%
-0.23
After Hours:
2.86
Dogwood Therapeutics Inc stock is traded at $2.86, with a volume of 34,271.
It is down -7.44% in the last 24 hours and down -9.78% over the past month.
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$3.09
Open:
$3.08
24h Volume:
34,271
Relative Volume:
0.72
Market Cap:
$95.23M
Revenue:
-
Net Income/Loss:
$-24.74M
P/E Ratio:
-0.1522
EPS:
-18.7859
Net Cash Flow:
$-15.75M
1W Performance:
+3.62%
1M Performance:
-9.78%
6M Performance:
-41.63%
1Y Performance:
-35.73%
1-Day Range:
$2.86
$3.1175
1-Week Range:
$2.75
$3.19
52-Week Range:
$2.60
$14.69
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
2.86 | 102.88M | 0 | -24.74M | -15.75M | -18.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
DWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Breakout Move: Does Dogwood Therapeutics Inc stock benefit from AI growthPortfolio Value Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Shorts Report: Is Dogwood Therapeutics Inc stock showing strong momentumDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Update: Does Dogwood Therapeutics Inc stock benefit from AI growthWeekly Stock Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Risk Off: What is the long term forecast for Dogwood Therapeutics Inc stockWeekly Market Outlook & AI Forecasted Entry/Exit Points - baoquankhu1.vn
DWTXDogwood Therapeutics Latest Stock News & Market Updates - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Earns Buy Rating from HC Wainwright - Defense World
Is Dogwood Therapeutics Inc. stock showing strong momentumMarket Volume Report & Growth Oriented Trading Recommendations - mfd.ru
What’s the MACD signal for Dogwood Therapeutics Inc.Trade Entry Summary & Reliable Entry Point Trade Alerts - mfd.ru
Market Wrap: How cyclical is Dogwood Therapeutics Incs revenue streamDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Pullback Watch: Whats the MACD signal for Dogwood Therapeutics Inc2025 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
What’s the analyst consensus on Dogwood Therapeutics Inc.July 2025 Gainers & Reliable Price Action Trade Plans - mfd.ru
Will Dogwood Therapeutics Inc. stock benefit from AI adoption2025 Winners & Losers & Weekly Top Performers Watchlists - mfd.ru
Will Dogwood Therapeutics Inc. benefit from geopolitical trendsEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru
Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan
How is Dogwood Therapeutics Inc. managing supply chain issuesQuarterly Portfolio Review & Low Risk Entry Point Guides - mfd.ru
What is the PEG ratio of Dogwood Therapeutics Inc.Weekly Profit Analysis & Accurate Buy Signal Notifications - mfd.ru
Why Dogwood Therapeutics Inc. stock could benefit from AI revolutionJuly 2025 Snapshot & Technical Confirmation Trade Alerts - mfd.ru
DWTX: Financing Secures Funding Through Phase 2b Data Readout - Smartkarma
Institution Moves: Will Dogwood Therapeutics Inc. benefit from geopolitical trends2025 Macro Impact & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 - markets.businessinsider.com
Cancer pain drug Halneuron shows early promise as major trial hits halfway - Stock Titan
What is Dogwood Therapeutics Inc.’s book value per share2025 Earnings Surprises & Low Risk Profit Maximizing Plans - mfd.ru
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Analysis Recap: Is AAON Inc impacted by rising ratesQuarterly Profit Review & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Price Action: What is the PEG ratio of Dogwood Therapeutics IncDip Buying & Stepwise Trade Signal Guides - baoquankhu1.vn
Dogwood Therapeutics outlines 2026 plans for pain pipeline - The Globe and Mail
Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge - MSN
Dogwood Therapeutics, Inc. Provides Corporate Update - TradingView — Track All Markets
Trend Report: Does ATUS stock have upside surprise potentialJuly 2025 Action & Verified Swing Trading Watchlists - baoquankhu1.vn
Retail Trends: Is Dogwood Therapeutics Inc stock showing strong momentumMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Support Test: Is Dogwood Therapeutics Inc stock showing strong momentumJuly 2025 Closing Moves & Advanced Technical Signal Analysis - baoquankhu1.vn
Dogwood Therapeutics Raises Capital via Registered Direct Financing - The Globe and Mail
Geopolitics Watch: Will Dogwood Therapeutics Inc stock maintain momentum in 2025Bull Run & Free Daily Entry Point Trade Alerts - Bộ Nội Vụ
Dogwood Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
Bull Run: Can Dogwood Therapeutics Inc stock sustain revenue growthJuly 2025 Breakouts & High Accuracy Trade Alerts - Bộ Nội Vụ
Risk Off: Whats Dogwood Therapeutics Incs historical return2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development - TradingView — Track All Markets
New funding backs a non-opioid drug for chemotherapy nerve pain - Stock Titan
Will Dogwood Therapeutics Inc. stock continue upward momentum2025 Year in Review & Stepwise Entry and Exit Trade Signals - ulpravda.ru
Will Dogwood Therapeutics Inc. stock recover faster than market2025 Major Catalysts & Capital Efficiency Focused Ideas - ulpravda.ru
Will Dogwood Therapeutics Inc. stock split again soonJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - Улправда
Why Dogwood Therapeutics Inc. stock is trending among retail tradersInsider Selling & Weekly Setup with High ROI Potential - ulpravda.ru
Can Dogwood Therapeutics Inc. stock hit record highs againJuly 2025 WrapUp & Fast Entry High Yield Tips - Улправда
What technical charts say about Dogwood Therapeutics Inc. stock2025 Performance Recap & Daily Entry Point Trade Alerts - Улправда
Momentum Shift: Will Dogwood Therapeutics Inc. stock recover faster than market2025 Major Catalysts & Capital Efficiency Focused Ideas - Улправда
How sustainable is Dogwood Therapeutics Inc. stock dividend payout2025 Earnings Surprises & Accurate Technical Buy Alerts - Улправда
Why Dogwood Therapeutics Inc. stock remains a top recommendationEx-Dividend Date Alerts & Rapid Wealth Building Tips - ulpravda.ru
Can Dogwood Therapeutics Inc. stock rebound after recent weaknessEarnings Season Recap & Add These Before Everyone Else Does - bollywoodhelpline.com
DWTX: Positive Interim Results for Halneuron Phase 2b Trial in CINP Raising Valuation to 15 - Research Tree
Aug Chart Watch: What hedge fund activity signals for Dogwood Therapeutics Inc stockProfit Target & Stock Portfolio Risk Management - moha.gov.vn
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):